1. Clinical features of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis: a new aspect of paraneoplastic autoimmune condition.
- Author
-
Urai, Shin, Iguchi, Genzo, Kanie, Keitaro, Bando, Hironori, Yamamoto, Masaaki, Oi, Yuka, Kashitani, Yuya, Iida, Keiji, Kanzawa, Maki, Fukuoka, Hidenori, Takahashi, Michiko, Shintani, Yasushi, Ogawa, Wataru, and Takahashi, Yutaka
- Subjects
ENDOCRINOLOGY ,PATHOGENESIS ,PARANEOPLASTIC syndromes ,IMMUNE checkpoint inhibitors ,CANCER immunotherapy ,ANTINEOPLASTIC agents - Abstract
The pathogenesis of anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis was gradually revealed as cases emerged. Our comprehensive analysis, including all reported cases, identified a new instance of anti-PIT-1 hypophysitis postimmune checkpoint inhibitor therapy. All 9 patients exhibited extremely low growth hormone (GH), prolactin (PRL), and thyroid-stimulating hormone (TSH) levels; 2 had a slightly atrophic pituitary gland; 4 had thymoma, and 5 had malignant neoplasms of diffuse large B-cell lymphoma (DLBCL) and other origins. Patients with thymoma showed multiple autoimmune diseases. HLA-A*24:02 and/or A*02:06 were present in six and DR53 in 5 cases analyzed. High anti-PIT-1 antibody titers and ectopic PIT-1 expression in the cytosol and nucleus of the tumor tissues were observed in patients with thymoma or DLBCL, whereas it was exclusively observed in the nuclei of a bladder cancer patient. These findings provide new insights into the pathophysiology of paraneoplastic autoimmune hypophysitis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF